Recently, Xuanzhu Biopharma Technology Co., Ltd. [hereinafter referred to as: Xuanzhu Biopharma] and the Thai pharmaceutical company Innobic (Asia) Co., Ltd. [hereinafter referred to as: Innobic (Asia)] and ZaoAn International Trading Co., Ltd. [ZaoAn International] formally signed a tripartite commercial agreement, granting exclusive commercialization rights for the core innovative drug Piridoxil Tablets (trade name: Xuanyuening®) in the Thailand region. This is another important progress in Xuanzhu Biopharma's internationalization layout, following the cooperation reached with Boston Oncology in April this year and the exclusive licensing and supply agreement for more than 20 countries in the Middle East and North Africa.

The implementation of this Thailand cooperation marks that Piridoxil has officially entered the core Southeast Asian market. As a core member state of PIC/S, Thailand has a mature pharmaceutical regulatory system. According to the agreement, Innobic (Asia), as the local distribution partner in Thailand, is fully responsible for the drug registration, marketing, and commercialization operations of Piridoxil in Thailand; ZaoAn International undertakes responsibilities related to procurement and payment; and Xuanzhu Biopharma provides product supply as agreed.

In the future, Xuanzhu Biopharma will use this as a fulcrum to continue expanding into other Southeast Asian countries, while actively advancing its layout in overseas markets such as Europe, and accelerating the benefit of China's original innovative drugs to cancer patients worldwide.

About Piridoxil Tablets

Piridoxil Tablets (trade name: Xuanyuening®), as the first approved CDK2/4/6 inhibitor in China, has a unique multi-target synergistic mechanism of action, with advantages such as potent inhibition of tumor cell proliferation and significantly reduced hematological toxicity commonly seen with traditional CDK4/6 inhibitors. Piridoxil Tablets were approved by China's National Medical Products Administration in May 2025 and March 2026 respectively for use in combination with fulvestrant for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) locally advanced or metastatic breast cancer patients who have experienced disease progression after prior endocrine therapy; as monotherapy for HR+/HER2- advanced or metastatic breast cancer patients who have experienced disease progression after receiving two or more endocrine therapies and one chemotherapy in the prior metastatic setting; and in combination with an aromatase inhibitor (AI) for first-line treatment of HR+/HER2- advanced breast cancer, becoming China's first and only CDK2/4/6 inhibitor approved with a monotherapy indication. In December 2025, both indications of Piridoxil Tablets approved in May 2025 were included in the "National Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance Drug List (2025)," effective from January 1, 2026.

About the Partners

01

About Innobic (Asia)

Innobic (Asia), a life sciences company in Thailand, mainly focuses on the Southeast Asian market while simultaneously exploring global commercial opportunities. Innobic (Asia) is a wholly owned subsidiary of PTT Public Company Limited (PTT), a listed company on the Stock Exchange of Thailand. As a national energy supplier and multinational enterprise group, PTT has invested in diversified new fields such as life sciences, renewable energy, and the power value chain. To date, PTT's revenue exceeds US$80 billion, and its market value exceeds US$33 billion. PTT's strategic goal in establishing Innobic (Asia) is to develop it into a leading life sciences company in the ASEAN market, focusing on businesses such as pharmaceuticals, medical technology, and nutrition.

02

About ZaoAn International

ZaoAn International is a trading company established in Hong Kong on September 17, 2021, with experience in cross-border pharmaceutical trade.

About Xuanzhu Biopharma

Xuanzhu Biopharma (Stock Code: 02575.HK) is an innovative pharmaceutical company rooted in China with a global vision, focusing on major disease areas such as digestion, oncology, and metabolism, and dedicated to the R&D, production, and commercialization of Class 1 new drugs with core independent intellectual property rights. As an emerging commercialization-oriented innovative drug company driven by R&D and empowered by AI, the company has built a technology system with coordinated interaction among a small molecule drug R&D platform, a biologics R&D platform, and an AI drug R&D platform, thereby forming a product pipeline rare in China that simultaneously covers multiple types such as small molecule chemical drugs, large molecule biologics, and antibody-drug conjugates. Guided by unmet clinical needs, the company is committed to developing into a first-class innovative drug enterprise with independent R&D, production, and sales capabilities.